A

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Associate Director of Marketing - KOL Engagement and Enablement

Marketing Generalist & ManagementConfirmed live in the last 24 hours
Full-timeRemote in USARemote

About the Job

Requirements

  • A bachelor's degree is required.
  • Experience building and leading advisory boards, the Thought Leader Liaison organization, and KOL strategy.
  • Eight or more years of experience in pharmaceutical or biotech marketing, healthcare consulting, or a healthcare agency, with a focus on HCP engagement, medical education, or peer-to-peer strategy is preferred.
  • Ability to navigate a dynamic, fast-paced environment by managing competing and complex priorities and engaging with cross-functional partners to ensure goals are met efficiently and collaboratively.
  • Meticulous attention to detail, ensuring accuracy, consistency, and quality across deliverables, communications, and project components.
  • Deep understanding of compliance requirements and experience in highly regulated environments.

Responsibilities

  • Develop and execute KOL-led education and training initiatives that enhance field team clinical expertise, scientific engagement capabilities, and understanding of key disease-state and brand messages.
  • Lead the strategy, development, implementation, and optimization of resources, tools, and engagement approaches that enhance TLL effectiveness and support meaningful KOL interactions.
  • Support the end-to-end KOL insights process, including strategic objective development, partnering on field training, insight collection, analysis, reporting, and dissemination of actionable insights across the organization.
  • Ensure TLL targets, KOL data, activities, insights, and records across Veeva and other systems are accurate, optimized, and compliant; proactively flag issues, support reporting, and drive operational process improvements.
  • Execute the U.S. TTR Commercial Advisory Boards to inform business decisions and strengthen engagement with external experts.
  • Establish and monitor metrics to evaluate the effectiveness of KOL engagement activities, educational initiatives, TLL resources, and insight generation programs while driving continuous improvement.
  • Partner with Medical Affairs, Commercial, Marketing, Legal, Compliance, and field leadership to align educational, engagement, and insight initiatives with organizational priorities and regulatory requirements.
  • Provide oversight of external agencies, vendors, and strategic partners supporting educational initiatives, content development, advisory boards, and engagement programs.
  • Maintain a deep understanding of the therapeutic area, healthcare professional educational needs, competitive landscape, and industry best practices to inform engagement and education strategies.
  • Identify and implement innovative approaches that strengthen KOL engagement, advance TLL capabilities, and increase organizational impact.

Desired Qualifications

  • An MBA or advanced degree in life sciences or marketing is preferred.
  • Eight or more years of experience in pharmaceutical or biotech marketing, healthcare consulting, or a healthcare agency, with a focus on HCP engagement, medical education, or peer-to-peer strategy is preferred.

About the Company

Alnylam Pharmaceuticals

Develops RNAi-based therapies for genetic diseases

Alnylam Pharmaceuticals develops RNA interference (RNAi) therapeutics to silence disease-causing genes, aiming to treat rare genetic disorders. Its products work by using RNA molecules that block gene expression, reducing the impact of specific genetic diseases. The company differentiates itself by concentrating on RNAi-based drugs for rare diseases and by building a pipeline through large clinical programs and strategic partnerships, such as commercialization deals in the Gulf States and collaborations with investors. Revenue comes from approved drug sales, licensing agreements, strategic collaborations, and related services like genetic testing and counseling. The company’s goal is to advance and commercialize RNAi therapies to improve outcomes for patients with genetic disorders, expanding its portfolio through partnerships and investments.

Company size
1,001-5,000
Company stage
IPO
Headquarters
Cambridge, MA
Founded
2002

Recently Posted Jobs

Explore more opportunities at Alnylam Pharmaceuticals

See more jobs